Skip to main content

Advertisement

Table 2 Resected colorectal adenocarcinoma patients analysed by immunohistochemistry for APRIL protein expression on tissue microarray

From: APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

Variable Frequency/median(range)
Age 71 years (22-92)
Gender  
Male 121
Female 113
Histological Grade  
Poor 27
Moderate 199
Well 8
Tumour site  
Proximal colon 79
Distal colon 86
Rectum 69
Stage  
I 46
II 86
III (adjuvant chemotherapy)1 102 (63)
   N2 48
  1. 1In this series 63/102 (62%) Stage III patients received adjuvant chemotherapy with 5FU